Rationale and results behind the use of breakthrough therapy-designated E-selectin antagonist for AML

The binding of E-selectin to leukemic cells has been shown to promote cell survival and chemotherapy resistance in acute myeloid leukemia (AML). In this interview, Daniel DeAngelo, MD, PhD, of Dana-Fa... Author: VJHemOnc Added: 02/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts